Company / Accounts Receivable
NovoCure Ltd Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$89.4M
FY2025
5-year range
$61.2M / $93.6M
FY2021-FY2025
Trend
+20.5%
vs FY2024
Sector context
#102 of 143
Health Care
What the data says
At $89M, NovoCure Ltd's accounts receivable ranks #102 of 143 in the Health Care sector. Improved from $61M to $89M over the past 2 years.
Based on SEC 10-K filings.
$89M in FY2025 with a 5-year CAGR of -1.5%.
Improved from $61M to $89M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +1.2%
- 5-Year CAGR
- -1.5%
- 10-Year CAGR
- -
Sector benchmark
#102 of 143 in Health CareTop 71% of 143This company $89.4M Sector average $1.3B
▼
-93.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.5%, indicating a declining trend.
- In FY2025, accounts receivable increased 20.5% year-over-year.
- Ranks #102 out of 143 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.4M | +20.5% |
| FY2024 | $74.2M | +21.2% |
| FY2023 | $61.2M | -29.0% |
| FY2022 | $86.3M | -7.8% |
| FY2021 | $93.6M | -3.2% |
| FY2020 | $96.7M | +64.3% |
| FY2019 | $58.9M | +61.2% |
| FY2018 | $36.5M | +23.5% |
| FY2017 | $29.6M | +366.4% |
| FY2016 | $6.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026